Zevra Therapeutics, Inc. (ZVRA)
Develops medicines for rare diseases like narcolepsy, excessive sleepiness, and genetic disorders.
$9.48-0.03%Healthcare
StockGlow Score
Neutral
BearishBullish
1 year ago-14.7%
The outlook
Analysts rate ZVRA as a Strong Buy with an average target about 164% above the current price of $9.48. The stock is trading well below its 50- and 200-day moving averages and sits near the lower end of its 52-week range, suggesting a downtrend. The overall sentiment is neutral despite the bullish analyst view, reflecting mixed market positioning.
What’s behind the score
Analyst consensusStrong Buy — 1.2 avg of 9 analysts
Price trendBelow its 50- & 200-day averages
52-week range29% of the way from its 52-week low to high
Price targetAvg target +164% vs current price
Analyst price target
~12-month · 9 analysts$25.00average target+163.7% vs now
Now $9.48
Low $20.00High $35.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$560.4M
52-wk high
$15.04
52-wk low
$7.16
50-day avg
$12.25
200-day avg
$10.13
Trailing P/E
4.7